Clinical Study

Optimizing Cns Dha Delivery In Elderly Adults At Risk For Dementia

Posted Date: Jan 7, 2025

  • Investigator: Robert Mcnamara
  • Specialties: Memory Disorders, Neurology, Psychiatry/Psychology
  • Type of Study: Drug

The purpose of this study is to test a new omega-3 fatty acid supplement. This new form of omega-3 may have better access to the brain than currently available omega-3 supplements. If we do find that this new supplement has better access to the brain, it could have a role in reducing risk for age-related memory decline.

Criteria:

Inclusion Criteria: 1) Men And Women 62 To 80 Years Old; 2) Presence Of Subjective Cognitive Decline; Exclusion Criteria: 1) Diagnosis Of Mci, Ad, Parkinson’S Disease, Frontotemporal Dementia, Multi-Infarct Dementia, Significant Head Trauma, Epilepsy, Leukoencephalopathy, Other Neurological Condition; 2) Self-Reported Emotional Disorder Such As Severe Depression Or Other Psychiatric Condition Causing A Persisting Decline In Functional Capability; 3) Diagnosis Of Atrial Fibrillation, Pancreatic, Liver, Kidney Or Hematological Coagulation Disorder; 4) Allergy To Shellfish Or Seafood; 5) Current Or Past Substance Use Causing Physiological Dependence Or Persisting Change In Functional Capability; 6) Concomitant, Regular Use Of Medications That Might Affect Outcome Measures Or Adversely Interact With The Study Product Including Anticoagulant Medications; 7) Weekly Fish Consumption >1 X 3 Oz Servings And/Or Use Of Dha-Containing Supplements Within 3 Months Prior To Screening.

Keywords:

Dementia, Elderly, Omega-3

For More Information:

Dawn Skirpan
513-558-8621
skirpadn@ucmail.uc.edu